The vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval.
Moderna announced on Aug. 28, 2020 that it is in discussions with the Ministry of Health, Labour and Welfare of Japan (MHLW) to purchase 40 million or more doses of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Through the agreement, the vaccine will be supplied by Moderna and distributed in Japan by Takeda Pharmaceutical starting in the first half of 2021 if the vaccine candidate receives regulatory approval, a Moderna press release said.
Source: Moderna
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.